Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells

Peilu Song(Tsinghua University), Maosheng Cheng(Shenyang Pharmaceutical University), Mingyu Xia(Shenyang Pharmaceutical University), Dahong Li(Shenyang Pharmaceutical University), Hanxun Wang(Shenyang Pharmaceutical University), Fan Zhao(Center for Life Sciences), Jian Wang(Shenyang Pharmaceutical University), Haitao Li(King Center), Feng Li(Tianjin University), Fengjiao Zhang(Shanghai Jiao Tong University), Yu Rao(Soochow University), Miaomiao Zhou(Shenyang Pharmaceutical University), Yuan Su(Shenyang Pharmaceutical University), Dongmei Zhao(Shenyang Pharmaceutical University), Miao Yao(Shenyang Pharmaceutical University), Yinli Gao(Ningbo University), Yujie Wang(Wuhan University), Jiqiang Qu(Shenyang Pharmaceutical University)
Acta Pharmaceutica Sinica B
March 4, 2022
10.1016/j.apsb.2022.02.029
Cited by 27

Related Papers

PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
Crystal structure of a bacterial homologue of glucose transporters GLUT1–4
|Nature|2012|488
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270